Changing the inhibitory specificity and function of the proteinase inhibitor eglin c by site-directed mutagenesis: functional and structural investigation.
Amino acids in the serine proteinase inhibitor eglin c important for its inhibitory specificity and activity have been investigated by site-directed mutagenesis. The specificity of eglin c could be changed from elastase to trypsin inhibition by the point mutation Leu45----Arg (L45R) in position P1 [nomenclature according to Schechter and Berger (1967) Biochem. Biophys. Res. Commun. 27, 157-162]. Model building studies based on the crystal structure of mutant L45R [Heinz et al. (1991) J. Mol. Biol. 217, 353-371] were used to rationalize this specificity change. Surprisingly, the double mutant L45R/D46S was found to be a substrate of trypsin and various other serine proteinases. Multidimensional NMR studies show that wild-type eglin c and the double mutant have virtually identical conformations. In the double mutant L45R/D46S, however, the N-H bond vector of the scissile peptide bond shows a much higher mobility, indicating that the internal rigidity of the binding loop is significantly weakened due to the loss or destabilization of the internal hydrogen bond of the P1' residue. Mutant T44P was constructed to examine the role of a proline in position P2, which is frequently found in serine proteinase inhibitors [Laskowski and Kato (1980) Annu. Rev. Biochem. 49, 593-626]. The mutant remains a potent elastase inhibitor but no longer inhibits subtilisin, which could be explained by model building. Both Arg51 and Arg53, located in the core of the molecule and participating in the hydrogen bonding network with residues in the binding loop to maintain rigidity around the scissile bond, were individually replaced with the shorter but equally charged amino acid lysine. Both mutants showed a decrease in their inhibitory potential. The crystal structure of mutant R53K revealed the loss of two hydrogen bonds between the core and the binding loop of the inhibitor, which are partially restored by a solvent molecule, leading to a decrease in inhibition of elastase by 2 orders of magnitude.
Heinz
D W
DW
Pharmaceutical Research Division, Ciba-Geigy Ltd., Basel, Switzerland.
Hyberts
S G
SG
Peng
J W
JW
Priestle
J P
JP
Wagner
G
G
Grütter
M G
MG
D000595:Amino Acid Sequence; D000818:Animals; D003461:Crystallography; D015195:Drug Design; D006860:Hydrogen Bonding; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D007865:Leeches / Q000201:enzymology; D046911:Macromolecular Substances; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D010196:Pancreatic Elastase / Q000037:antagonists & inhibitors; D011485:Protein Binding; D011487:Protein Conformation; D011506:Proteins; D015842:Serine Proteinase Inhibitors / Q000737:chemistry* / Q000378:metabolism; D015843:Serpins; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D013381:Subtilisins / Q000037:antagonists & inhibitors; D013696:Temperature; D014361:Trypsin Inhibitors / Q000737:chemistry; D014961:X-Ray Diffraction
D046911:Macromolecular Substances; D011506:Proteins; D015842:Serine Proteinase Inhibitors; D015843:Serpins; D014361:Trypsin Inhibitors; C028656:eglin proteinase inhibitors; D013381:Subtilisins; D010196:Pancreatic Elastase